Abstract. The Hippo pathway, a critical cell proliferation regulator, remains an underexplored oncogenic pathway in precision oncology. It is executed through YAP1/TAZ co-activators and the TEAD ...

Multiple lines of correlative evidence support a role for angel homolog 2 (ANGEL2), a novel cancer-relevant RNA-binding protein, in the modulation of chemoresistance and survival of patients with ...

Abstract. Many cancers are curable if treated in time. This is the keynote of the educational campaign for the control of cancer. To reduce the delay in treatment is the first step in lessening the ...

The Cancer and Leukemia Group B (CALGB) began to take shape in 1953 when James F. Holland arrived at the National Cancer Institute (NCI) upon the opening of the Clinical Center and initiated a ...

AbstractPurpose:. Antibody–drug conjugates (ADC) are a promising approach for the management of patients with non–small cell lung cancer (NSCLC). However, only a small subset of patients derive ...

It is well known that the majority of genetic variants or single nucleotide polymorphisms in the human genome are of low penetrance, including genes implicated in metabolism of environmental chemicals ...

Preclinical activity of onvansertib was assessed (i) in vitro in KRAS wild-type and -mutant isogenic colorectal cancer cells and (ii) in vivo, in combination with irinotecan, in a KRAS -mutant ...

Abstract. The cancer early-detection biomarker field was, compared with the therapeutic arena, in its infancy when the Early Detection Research Network (EDRN) was initiated in 2000. The EDRN has ...

Cervical cancer is a relatively rare disease in countries that have instituted and maintained national screening programs, with call and recall of women at various intervals and built-in quality ...

This work demonstrates that METTL3 inhibition stimulates a cell-intrinsic interferon response through dsRNA formation. This immunomodulatory mechanism is distinct from current immunotherapeutic agents ...

2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025Online ISSN 2159-8290 Print ISSN 2159-8274 ...

Abstract. Background: ASC63 is an oral small molecule programmed cell death-ligand 1 (PD-L1) inhibitor. After oral dosing, ASC63 is rapidly absorbed and converted to its pharmacologically active ...